In:
Oncology, S. Karger AG, Vol. 80, No. 3-4 ( 2011), p. 175-180
Abstract:
〈 i 〉 Objective: 〈 /i 〉 Our aim was to devise a prognostic model for advanced pancreatic cancer based on clinical parameters. 〈 i 〉 Methods: 〈 /i 〉 We retrospectively analyzed the medical records of 298 patients who received gemcitabine-based chemotherapy from January 1999 to November 2008. 〈 i 〉 Results: 〈 /i 〉 The median survival of all patients was 7 months [95% confidence interval (CI) 6.2–7.8]. Multivariate analysis revealed poor prognostic factors for overall survival such as the presence of liver metastasis [p 〈 0.001, hazard ratio (HR) 2.628, 95% CI 1.620–4.264], the presence of ascites or peritoneal carcinomatosis (p = 0.005, HR 1.783, 95% CI 1.194–2.661), serum C-reactive protein levels 〉 1.2 mg/dl (p = 0.021, HR 1.568, 95% CI 1.070–2.300), and serum albumin levels 〈 3.5 g/dl (p = 0.021, HR 1.701, 95% CI 1.085–2.667). Of 298 patients, 168 patients (56.4%) were categorized as low-risk with 0 or 1 risk factor, 80 patients (26.8%) were categorized as intermediate-risk with 2 risk factors, and 50 patients (16.8%) were categorized as high-risk with 3 or 4 risk factors. The median survival duration for the low-, intermediate-, and high-risk groups was 10.0 months (95% CI 8.7–11.3), 6.7 months (95% CI 5.7–7.7), and 4.4 months (95% CI 3.2–5.6), respectively. 〈 i 〉 Conclusions: 〈 /i 〉 This prognostic model could help to select treatment for patients in clinical practice, and these risk-adapted treatment strategies should be further investigated in prospective studies in such patient populations.
Type of Medium:
Online Resource
ISSN:
0030-2414
,
1423-0232
Language:
English
Publisher:
S. Karger AG
Publication Date:
2011
detail.hit.zdb_id:
1483096-6
detail.hit.zdb_id:
250101-6
Permalink